Zobrazeno 1 - 10
of 37
pro vyhledávání: '"M. V. Shapina"'
Autor:
V. T. Ivashkin, I. V. Maev, Yu. A. Shelygin, E. K. Baranskaya, S. S. Belous, E. A. Belousova, A. G. Beniashvili, S. V. Vasilyev, A. V. Veselov, E. G. Grigoryev, N. V. Kostenko, V. N. Kashnikov, V. F. Kulikovskiy, I. D. Loranskaya, O. S. Lyashenko, E. A. Poluektova, V. G. Rumyantsev, V. M. Timerbulatov, O. Yu. Fomenko, D. A. Khubezov, E. Yu. Chashkova, G. I. Chibisov, M. V. Shapina, A. A. Sheptulin, O. S. Shifrin, A. S. Trukhmanov, O. P. Alekseeva, S. A. Alekseenko, A. Yu. Baranovsky, O. Yu. Zolnikova, N. V. Korochanskaya, S. N. Mammayev, I. B. Khlynov, V. V. Tsukanov
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 31, Iss 5, Pp 74-95 (2022)
Aim. Current clinical recommendations accentuate current methods for the diagnosis and treatment of irritable bowel syndrome (IBS).Key points. IBS is a functional bowel disorder manifested with recurrent, at least weekly, abdominal pain with the foll
Externí odkaz:
https://doaj.org/article/030ee14fec6f4a7ea68f1f334c304c3b
Autor:
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeysh, M. V. Shapina, O. B. Shchukina
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 48, Iss 6, Pp 422-436 (2020)
Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and commonly result in disability. Therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorabl
Externí odkaz:
https://doaj.org/article/c0aa6e2e135a47ddb79fd4af90add98d
Autor:
A. V. Poletova, M. V. Shapina
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 128-133 (2020)
Introduction. Despite improvements in earlier diagnosis and the development of conservative therapy for Crohn’s disease (CD), approximately 70%–80% of patients undergo surgical treatment for complications. Surgical treatment is not a cure for thi
Externí odkaz:
https://doaj.org/article/cb45efcf86e542ae9ef891f3da623dc1
Autor:
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina, O. B. Shchukina
Publikováno v:
Современная ревматология, Vol 14, Iss 3, Pp 7-18 (2020)
Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and frequently lead to disability; therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorabl
Externí odkaz:
https://doaj.org/article/e338338809204dbd8dc7334092900e55
Publikováno v:
Медицинский совет, Vol 0, Iss 5, Pp 114-119 (2020)
The article presents data of some skin diseases, that often appear in inflammatory bowel diseases (IBD).Some of the skin diseases are directly connected with the activity of the main inflammatory process (erythema nodosum, Crohn’s disease of the sk
Externí odkaz:
https://doaj.org/article/5289095bf47d4f85a3e5b8d96d2dcd9f
Autor:
M. V. Shapina, B. A. Nanaeva
Publikováno v:
Терапевтический архив, Vol 92, Iss 2, Pp 67-73 (2020)
Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown in clinical trials. This article presents the experience of using vedolizumab in real clin
Externí odkaz:
https://doaj.org/article/bda8c5011b7e4f6fbc2096f56751b4f8
Autor:
Igor L. Khalif, M. V. Shapina
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 6, Pp 92-100 (2018)
Aim of review. To present literature data on administration of vedolizumab at inflammatory bowel diseases. Summary. The vedolizumab is anti-α4β7-integrin humanized class IgG1 antibodies which suppresses migration of leukocytes in intestinal tissue,
Externí odkaz:
https://doaj.org/article/3d9b5a4cea044ac6a89ee5f9016ce2b0
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 5, Pp 74-81 (2018)
Aim of investigation. To determine the content of growth factors (G-CSF, GM-CSF) and chemokines (MCP-1, MIP-1β) in resected colon specimens of patients with severe ulcerative colitis (UC). Material and methods. Overall 48 biopsy specimens of the col
Externí odkaz:
https://doaj.org/article/f0d09900b25c46cdbc0ce3741067957d
Autor:
L. . Khalif, M. V. Shapina, A. O. Golovenko, Ye. A. Belousova, Ye. Yu. Chashkova, A. V. Lakhin, O. V. Knyazev, A. Yu. Baranovsky, N. N. Nikolayeva, A. V. Tkachev
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 28, Iss 3, Pp 54-62 (2018)
Aim of investigation. To evaluate the prevalence of clinical manifestations and variants of progression for ulcerative colitis (UC) and Crohn’s disease (CD) in population of the Russian Federation. Material and methods. The present investigation wa
Externí odkaz:
https://doaj.org/article/a2c8cc4031bf4052989435830967b522
Autor:
M. V. Shapina, I. L. Khalif
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 44-50 (2017)
Preparations of 5-ASA are the first line treatment of ulcerative colitis (UC). Today, in the market of drugs 5-ASA available for the treatment of UC, there are many dosage forms, varying in the coating, method of delivery of active substance and dosi
Externí odkaz:
https://doaj.org/article/84fe74cd3baf4157ba0ce930f401130b